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Stem cell transplantation (SCT) involves a great risk of acute kidney injury (AKI). Urinary liver-type fatty acid-
binding protein (uL-FABP) is a sensitive biomarker to detect kidney damage before an increase in serum
creatinine (Cr); however, the utility of uL-FABP is not fully understood in the platform of SCT. A prospective
study was conducted in 84 allogeneic SCT recipients to ascertain a link between the uL-FABP level before
preparative procedures and AKI incidence after SCT. The association between themwas analyzed using Gray’s
method and a multivariate Fine-Gray proportional hazards regression model. The recipients were stratiﬁed
into high and low uL-FABP groups, according to the reference value for healthy subjects (8.4 mg/g Cr). AKI
developed more frequently in the high (n ¼ 20) than low (n ¼ 64) group (55.0% versus 26.6% at day 30,
P ¼ .005), and high uL-FABP was an independent risk for the emergence of AKI (hazard ratio, 2.78; 95%
conﬁdence interval, 1.24 to 6.22, P ¼ .01). In conclusion, increased baseline uL-FABP, which may indicate
previous incipient kidney injury, is linked with a high risk of AKI after allogeneic SCT.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION minor yet signiﬁcant kidney injury in SCT candidates and
Allogeneic stem cell transplantation (SCT) involves a great
risk of acute kidney injury (AKI) [1-3]. Previous papers have
shown that the frequency of AKI rose to as high as 69% in
allogeneic SCT [4], post-SCT AKI affected poor short- and
long-term survival in patients [5-8], mortality increased with
the severity of AKI, and post-SCT AKI is a risk factor for
chronic kidney disease in long-term survivors [6,7,9]. In the
setting of SCT, the measurement of serum creatinine (Cr) is
perhaps considered to be the gold standard for identifying
the existence or emergence of kidney disease. However, the
serum Cr level never reﬂects incipient kidney tubular injury
or ischemic tissue damage before a decrease in glomerular
function, which could be a risk for the progression to chronic
kidney disease. The utilization of newly discovered urinary
biomarkers may contribute to early identiﬁcation of suchedgments on page 2014.
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ty for Blood and Marrow Transplantation.predict the emergence of AKI after SCT in such patients.
Liver-type fatty acid-binding protein (L-FABP) is a 15 kDa
protein expressed in human renal proximal tubular cells.
L-FABP binds fatty acids and transports them to mitochon-
dria or peroxisomes, and it contributes to intracellular fatty
acid homeostasis [10]. Urinary L-FABP (uL-FABP), shed into
urine in response to renal tissue ischemia [11,12] or oxidative
stress, has been reported to be useful for the early detection
of AKI in patients who have undergone cardiac surgery [13]
and had contrast media-induced nephropathy [14]. In addi-
tion, uL-FABP levels over the upper limit of the reference
value may reﬂect the existence of subclinical kidney disease
that can progress to overt diabetic nephropathy in patients
with type 2 diabetes [15].
As the utility of uL-FABP is not fully understood in the
clinical platform of SCT, we measured baseline uL-FABP
before conditioning therapy and assessed whether the
values are useful in identifying patients at increased risk of
AKI after SCT.
MATERIALS AND METHODS
Study Design
This study was an observational prospective study in allogeneic SCT
recipients. Written informed consent was obtained from all participants
N. Shingai et al. / Biol Blood Marrow Transplant 20 (2014) 2010e2014 2011before initiating conditioning therapy for SCT. The study was performed in
accordance with the Declaration of Helsinki and was approved by the
institutional committee on research ethics.Study Subjects
Two hundred and six patients received allogeneic SCT fromMarch 2009
to March 2012 at Tokyo Metropolitan Cancer Center, Komagome Hospital.
The inclusion criteria at entry were as follows: (1) age over 16 years; (2)
recipients of their ﬁrst allogeneic transplantation; and (3) absence of
glomerular dysfunction at baseline, deﬁned as an estimated glomerular
ﬁltration rate (eGFR) less than 60 mL/minute/1.73 m2. In total, 84 partici-
pants were eligible for the study.Preparative Procedures for SCT
Patients with lymphoid malignancies were generally conditioned with
total body irradiation (TBI, 12 Gy) and cyclophosphamide (CY, 120 mg/kg),
with or without cytarabine (8 g/m2). Most patients with myeloid malig-
nancies were conditioned with a regimen of busulfan (BU,16mg/kg orally or
12.8 mg/kg intravenously) and CY (120 mg/kg). Most patients undergoing
the reduced nonmyeloablative conditioning regimen received ﬂudarabine
(125mg/m2), melphalan (80mg/m2), and low-dose TBI (4 Gy) or ﬂudarabine
(180 mg/m2), BU (6.4 mg/kg intravenously), and low-dose TBI. Patients with
aplastic anemiawere conditioned with total lymphoid irradiation (7 Gy) and
CY (200 mg/kg). Conditioning regimens including TBI 8 Gy, melphalan
140 mg/m2, or oral BU 9 mg/kg (intravenous BU 7.2 mg/kg) were
deﬁned as myeloablative conditioning (MAC); other regimens were deﬁned
as reduced-intensity conditioning [16]. Graft-versus-host disease prophy-
laxis consisted of a short course of methotrexate and calcineurin inhibitor
(cyclosporine A or tacrolimus). Tacrolimus was used in cases of either un-
related or HLA-mismatched SCT. Basically, the employed prophylaxis drugs
were new quinolones for bacterial infection, ﬂuconazole or itraconazole for
fungal infection, and acyclovir for herpes virus infection.Deﬁnitions and Data Collection
AKI was deﬁned and graded according to the Acute Kidney Injury
Network criteria: stage 1, increase in serum Cr  1.5  baseline or .3 mg/dL;
stage 2, increase in serum Cr 2.0 baseline; and stage 3, increase in serum
Cr 3.0 baseline [17]. AKI that developedwithin the ﬁrst 30 days after SCT
was considered in this study, as the prognosis of SCT recipients was much
worse in those who developed AKI in this time window after SCT [3,18].
Baseline serum Cr was measured before starting conditioning therapy. eGFR
was calculated based on the serum Cr concentration, using the following
equation: eGFR (mL/minute/1.73 m2) ¼ 194  Cr1.094  age.287  .739 (if
female), which was constructed for the Japanese population by the Japanese
Society of Nephrology because of the inaccuracy of the modiﬁed modiﬁca-
tion of diet in renal disease equation for Asian people, including Japanese
[19]. uL-FABP was measured before initiating conditioning therapy to
identify pre-existing subclinical kidney disease in the absence of a decline in
eGFR. Serum Cr was measured every 2 or 3 days before and after stem cell
infusion. Spot urine samples were collected in the morning fasting state,
quickly centrifuged at 2000 rpm for 5 minutes at 4C, and stored at 80C
until the measurements were made. uL-FABP concentrations were
measured by the enzyme-linked immunosorbent assay (ELISA) using a hu-
man L-FABP ELISA Kit (CIMIC, Tokyo, Japan) according to the manufacturer’s
protocol [20]. uL-FABP concentrations were corrected by urine Cr concen-
trations to compensate for differences in urine ﬂow rate. The serum and
urine Cr was measured by an enzymatic method, using the N-assay L
Creatinine Kit (Nittoubo Medical Co., Tokyo, Japan). uL-FABP levels were
expressed as micrograms per gram of Cr. The recipients were stratiﬁed into
high and low uL-FABP groups according to the reference values of 412
healthy volunteers (<8.4 mg/g Cr) [15]. Disease risk was classiﬁed as either
standard or high risk. Acute leukemia in the ﬁrst or second complete
remission; chronic myeloid leukemia in the ﬁrst chronic phase; Hodgkin or
non-Hodgkin lymphoma in complete or partial chemotherapy-sensitive
remission, myelodysplastic syndrome, or myeloproliferative disorder
without excess blasts were considered standard risk and all others were
determined to be high risk at the time of transplantation [21].
The hematopoietic cell transplantation-speciﬁc comorbidity index
(HCT-CI) is an integrated scoring of pretransplantation comorbidities
including cardiac, pulmonary, hepatic, and renal disorders that are consid-
ered to affect prognosis after SCT, which is commonly used in evaluating
risks in SCT recipients. HCT-CI score<3 was deﬁned as low, whereas3 was
deﬁned as high [22,23]. Hypertensionwas deﬁned as systolic blood pressure
140 mmHg and/or diastolic blood pressure 90 mmHg or the use of
antihypertensive agents at baseline. Diabetes mellitus (DM)was deﬁned as a
diagnosis of DM before baseline or the use of oral antidiabetic agents or
insulin at baseline.Statistics
Two groups were compared using the Mann-Whitney U-test for contin-
uous variables and Fisher exact test for categorical variables. The cumulative
incidence of AKI was estimated and compared using Gray’s method, consid-
ering death without AKI as a competing risk. The association of AKI incidence
over time after SCT and uL-FABP elevation before the conditioning chemo-
therapy was analyzed using a multivariate Fine-Gray proportional hazards
model. In univariate analyses, the following known risk factors were assessed
as confounders: age (49 or < 49 years, the median of all recipients), sex,
disease risk (standard or high), HCT-CI (3 or< 3), the presence or absence of
hypertension and DM, stem cell sources, pretransplantation chemotherapy on
the day of data sampling, pretransplantation infection requiring treatment on
the day of data sampling, HLA compatibility (matched or mismatched), con-
ditioning regimens (MAC or reduced-intensity conditioning), the presence or
absence of TBI, the use of cyclosporin A or tacrolimus, abnormal elevation of
calcineurin inhibitor concentration (cyclosporineA> 400 ng/mLor tacrolimus
>20 ng/mL), a surge of blood pressure after calcineurin inhibitor use, and the
development of thrombotic microangiopathy, sinusoidal obstruction syn-
drome, sepsis, and grade II to IV acute graft-versus-host disease. A multivar-
iable model was constructed incorporating confounders with borderline
statistical signiﬁcance (P < .20) in univariate analyses. The odds ratio with its
95% conﬁdence interval (CI) for the incidence of AKI was calculated. All sta-
tistical tests were 2-sided, with P < .05 considered signiﬁcant. All data were
analyzed using R, version 2.14.0 (http://www.r-project.org/).
RESULTS
Characteristics of the Patients
A total of 84 patients, including 48 men and 36 women,
were included consecutively in the study. Patient character-
istics are summarized in Table 1. The median patient age was
49 (range, 16 to 69) years. Patients had been diagnosed with
acute myeloid leukemia (n ¼ 36), acute lymphoid leukemia
(n¼ 22), myelodysplastic syndrome (n¼ 17), chronic myeloid
leukemia (n ¼ 4), aplastic anemia (n ¼ 3), primary myeloﬁ-
brosis (n ¼ 1), and malignant lymphoma (n ¼ 1). Twenty
patients were classiﬁed into the high uL-FABP group and 64
into the lowuL-FABP group. SerumCr levels were not different
between the 2 groups. Patients were older in the high uL-FABP
group (P ¼ .04). The proportion of high-risk disease was
signiﬁcantly greater in the high than in the low uL-FABP group
(P ¼ .008). There were no signiﬁcant differences in the pro-
portion of men, HCT-CI 3, hypertension, DM, pre-
transplantation chemotherapy, pretransplantation infection,
matched HLA compatibility, and use of MAC regimen.
Association of uL-FABP Level before Conditioning
Therapy with the Incidence of AKI after SCT
The cumulative incidence of AKI after SCT was 36.9% (95%
CI, 23.0% to 42.3%) at day 30 (n ¼ 31), and the median time to
occurrence was 14 days (range, 0 to 30 days) after SCT, as
shown in Figure 1. According to the Acute Kidney Injury
Network criteria, 6 patients developed stage 1 (19.3%), 14
patients stage 2 (45.2%), and 11 patients stage 3 (35.5%). Four
AKI patients (12.9%) required renal replacement therapy
(RRT): 2 in the high uL-FABP group (10.0%) and 2 in the low
uL-FABP group (4.7%), respectively. The cumulative incidence
of AKI at day 30 was signiﬁcantly higher in the high than in
the low uL-FABP group (55.0% versus 26.6%, P ¼ .005)
(Figure 2). In the univariate analyses, older age, high disease
risk, HCT-CI 3, the presence of hypertension, and high
uL-FABP at baseline were signiﬁcantly related to the devel-
opment of AKI, as shown in Table 2. Post-transplantation
infections, including septic syndrome and diarrhea due to
Clostridium difﬁcile, which are linked with electrolyte abnor-
malities, ﬂuid resuscitation, and intravenous administration of
antibiotics, may worsen renal function. A total of 32 patients
developed post-transplantation infection, 7 in whom were
affected by 2 or more infections. Post-transplantation
infections included 21 bloodstream infection;
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Figure 1. Cumulative incidence of acute kidney injury (AKI) over time after
stem cell infusion. The curve indicates the cumulative incidence of AKI over
time from the day of stem cell infusion to day 30 after infusion. A total of 31
SCT recipients developed AKI within 30 days after allogeneic SCT. The cumu-
lative incidence of AKI was 36.9% at day 30.
Figure 2. Cumulative curves of the incidence of AKI, stratiﬁed by high and low
Table 1
Patient Characteristics at Baseline
Variable Low uL-FABP
Group
High uL-FABP
Group
P
Value
Patients 64 (76) 20 (24)
Age, median (range), yr 47.5 (16-69) 59.5 (28-69) .04
Serum Cr, median
(range), mg/dL
.6 (.3-.9) .6 (.5-.9) .73
eGFR, median (range),
mL/min/1.73 m2
92.9 (64.3-168.4) 91.0 (65.1-130.4) .62
Sex
Male 36 (56) 12 (60) .80
Female 28 (44) 8 (40)
Disease risk
Standard 45 (70) 7 (35) .008
High 19 (30) 13 (65)
HCT-CI
<3 50 (78) 13 (65) .25
3 14 (22) 7 (35)
Hypertension
Yes 15 (23) 3 (15) .54
No 49 (77) 17 (75)
DM
Yes 5 (8) 0 (0) .33
No 59 (92) 20 (100)
Stem cell source
Related BMT 2 (3) 1 (5) .28
Unrelated BMT 46 (72) 18 (90)
Related PBSCT 6 (9) 0 (0)
Unrelated CBT 10 (16) 1 (5)
Pretransplantation
chemotherapy
Yes 9 (14) 1 (5) .44
No 55 (86) 19 (95)
Pretransplantation
infection
Yes 12 (19) 7 (35) .14
No 52 (81) 13 (65)
HLA compatibility
Matched 40 (63) 13 (65) 1.00
Mismatched 24 (38) 7 (35)
Conditioning regimen
MAC 47 (73) 12 (60) .27
RIC 17 (27) 8 (40)
BMT indicates bone marrow transplantation; PBSCT, peripheral blood stem
cell transplantation; CBT, cord blood transplantation; RIC, reduced-intensity
conditioning.
Data presented are n (%) unless otherwise indicated.
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pneumonia; 4 invasive fungal infection, including 2 aspergil-
losis and 2 candidiasis; and 2 viral encephalitis. Incidence of
post-transplantation infections was assessed as a covariate for
the development of AKI in the univariate analysis; however, it
was not signiﬁcant (37.5% [95% CI, 21.0% to 54.0%] versus 30.8%
[95% CI, 18.8% to 43.6%], P ¼ .51). In multivariate analysis, the
incidence of AKI after SCT was signiﬁcantly associated with
high uL-FABP (hazard ratio [HR], 2.78; 95% CI, 1.24 to 6.22;
P ¼ .01), hypertension at baseline (HR, 3.16; 95% CI, 1.14 to
8.75; P¼ .03), and the presence of HCT-CI3 (HR, 3.44; 95% CI,
1.56 to 7.61; P ¼ .002), as shown in Table 3. Nonrelapse death
occurred in 8 patients (9.5%; 8 out of 84 recipients) within
100 days after SCT. Of them, all patients developed AKI, and 6
out of 8 patients (75%) had been classiﬁed into the high uL-
FABP group. Causes of nonrelapse death included 4 multiple
organ failures accompanying AKI, 3 refractory bacterial
pneumonias, and 1 systemic fungal infection.uL-FABP levels. The recipients were stratiﬁed into high and low uL-FABP
groups according to the normal reference value (8.4 mg/gCr). The cumulative
incidence of AKI at day 30 was signiﬁcantly higher in the high than low
uL-FABP group (55.0% versus 26.6%, P ¼ .005). Asterisk (*) indicates the sig-
niﬁcant difference between the 2 curves. AKI indicates acute kidney injury;
uL-FABP, urinary liver-type fatty acid-binding protein.DISCUSSION
To our knowledge, this is the ﬁrst study showing the
utility of uL-FABP measurements in the clinical setting ofallogeneic SCT. The cumulative incidence of AKI was
increased in SCT patients with baseline uL-FABP higher than
the normal reference value. As our study excluded patients
with a baseline decrease in eGFR, the pre-existing minor
structural or functional kidney disease lacking a decline in
glomerular function may contribute to the development of
AKI after SCT.
Our study indicated that the presence of subclinical kid-
ney injury, likely renal tubular and/or ischemic tissue dam-
age, may portend the incidence of overt AKI after allogeneic
SCT, when renal and/or systemic stress, including trans-
plantation preparative regimens, is exerted on the body. The
impact of previous minor kidney damage on the subsequent
emergence of overt AKI has been reported in some clinical
Table 2
Univariate Analysis of Risk Factors for AKI at Day 30
Variables n Cumulative
Incidence (95% CI)
P Value
Age, yr
<49 40 22.5 (11.0-36.5) .04
49 44 43.2 (28.2-57.3)
Sex
Female 36 33.3 (18.5-48.9) .99
Male 48 33.3 (20.4-46.8)
Disease risk
Standard 52 26.9 (15.7-39.5) .04
High 32 43.8 (26.1-60.1)
HCT-CI
<3 63 23.8 (14.1-34.9) <.001
3 21 61.9 (37.0-79.4)
Hypertension at baseline
No 66 25.8 (15.9-36.8) .007
Yes 18 61.1 (33.9-79.9)
DM at baseline
No 79 32.9 (22.8-43.4) .81
Yes 5 40.0 (3.1-78.6)
Stem cell source
Related BMT 3 33.3 (.1-83.2) .31
Unrelated BMT 64 28.1 (17.7-39.5)
Related PBSCT 6 66.7 (12.2-92.5)
Unrelated CBT 11 45.5 (15.1-72.0)
Pretransplantation
chemotherapy
No 74 33.8 (23.2-44.6) .79
Yes 10 30.0 (6.2-59.3)
Pretransplantation infection
No 65 29.2 (18.7-40.6) .09
Yes 19 47.4 (23.6-67.9)
uL-FABP
Low 64 26.6 (16.4-37.8) .005
High 20 55.0 (30.4-74.1)
HLA compatibility
Matched 53 32.1 (20.0-44.8) .74
Mismatched 31 35.5 (19.1-52.3)
Conditioning regimen
MAC 59 28.8 (17.8-40.7) .18
RIC 25 44.0 (24.0-62.4)
TBI
No 34 35.3 (19.7-51.3) .87
Yes 50 32.0 (19.6-45.1)
CNIs
Cyclosporin 24 41.7 (21.7-60.5) .37
Tacrolimus 60 30.0 (18.9-41.9)
Abnormal elevation of CNIs
No 45 33.3 (20.0-47.2) .98
Yes 39 33.3 (19.1-48.3)
Surge of blood pressure
after CNI use
No 65 30.0 (11.8-50.7) .67
Yes 19 36.8 (15.9-58.1)
TMA
No 79 34.2 (23.9-44.7) .48
Yes 5 20.0 (.4-62.1)
SOS
No 81 32.1 (22.2-42.4) .13
Yes 3 66.7 (0-97.3)
Post-transplantation infection
No 52 30.8 (18.8-43.6) .51
Yes 32 37.5 (21.0-54.0)
Acute GVHD (grade II-IV)
No 58 36.2 (24.0-48.5) .32
Yes 26 26.9 (11.7-44.9)
CNI indicates calcineurin inhibitor; TMA, thrombotic microangiopathy; SOS,
sinusodal obstruction syndrome; GVHD, graft-versus-host disease.
Table 3
Multivariate Analysis of Risk Factors for AKI at Day 30
Variables n Hazard Ratio (95% CI) P Value
Age, yr
<49 40 1 .91
49 44 1.06 (.39-2.9)
Disease risk
Standard 52 1 .14
High 32 1.78 (.82-4.0)
HCT-CI
<3 63 1 .002
3 21 3.44 (1.56-7.61)
Hypertension at baseline
No 66 1 .03
Yes 18 3.16 (1.14-8.75)
Pretransplantation infection
No 65 1 .50
Yes 19 1.37 (.58-3.23)
uL-FABP
Low 64 1 .01
High 20 2.78 (1.24-6.22)
Conditioning regimen
MAC 59 1 .71
RIC 25 1.23 (.42-3.58)
SOS
No 81 1 .12
Yes 3 2.99 (.76-11.8)
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baseline albuminuria (urine albumin to Cr ratio) has a graded
associationwith the incidence of AKI, independent of eGFR at
baseline in a prospective cohort of 11,200 participants in the
Atherosclerosis Risk in Communities study [26]. Generally,SCT candidates need to undergo repetitive chemotherapies,
including some nephrotoxic agents for treating underlying
hematological malignancies, until achieving complete or
partial remission. In addition, they usually receive antibac-
terial, antifungal, and antiviral drugs during the period.
This study showed that high-risk diseasewas signiﬁcantly
associated with elevation of uL-FABP. High-risk disease pa-
tients were thought to receive frequent chemotherapies and
develop severe infections before transplantation; however,
neither pretransplantation chemotherapy nor infectionwere
associated with elevation of uL-FABP. This may indicate that
the elevation of baseline uL-FABP was induced by some
complex and diverse factors. These factors are likely to cause
insidious structural and/or functional kidney injury, the de-
gree of which cannot be quantiﬁed by a conventional urine
test or serum Cr measurement. It is well known that several
substances that are involved in the pathophysiologic process
of kidney injury and renal tubular cell death are released into
urine. Among them, uL-FABP may be one of the most
promising new biomarkers for the purpose of detecting
occult yet substantial kidney disease, as its elevated levels
predict the future appearance of solid kidney disease after
treatments potentially detrimental to the kidney and the
acute worsening of prevalent nephropathies [12,14,20,27].
A previous study showed that elevation of uL-FABP is a
harbinger of the progression of AKI and requirement of RRT
[28]. Nonrelapse death occurred in 8 patients, all of whomhad
developed AKI. In this study, the 4 AKI patients who required
RRT died of multiple organ failure related to AKI. Although
RRT is often effective for correcting disorders of toxins, elec-
trolytes and ﬂuid overload, it is not necessarily successful. The
efﬁcacy of dialysis therapy often depends on the timing of its
initiation. Once patients have hemodynamic instability,
continuing RRT becomes difﬁcult and sometimes impossible.
Post-SCT AKI is a life-threatening comorbidity for SCT, and
thus, early initiation of RRT is sometimes warranted; however,
waiting for an increment in serum Cr, which is a common
determinant of RRT indication, may delay the decision to
initiate dialysis therapy in some AKI cases after SCT. Our result
may suggest that consecutive measurements of uL-FABP
N. Shingai et al. / Biol Blood Marrow Transplant 20 (2014) 2010e20142014during SCT procedures is a promising tool for not only
detecting hidden subclinical kidney injury but also making a
rapid decision of preemptive treatment for AKI.
This study has several limitations. First, themajor etiology
of previous subclinical kidney disease, which is identiﬁed by
increased uL-FABP, was not proven by a renal biopsy, as it is
generally unfeasible in the period of SCT because of the
perceived risks. In fact, the renal histological ﬁndings in SCT
recipients in the absence of renal dysfunction are not fully
understood [29,30]. In cases of severe post-SCT AKI, Zager
et al. [31] reported that autopsy kidney specimens provided
no clear explanation for AKI in the vast majority of 36 post-
SCT AKI patients who had no prior clinical kidney disease,
and thus, they speculated that renal functional impairment is
usually hemodynamic, rather than structural, in nature.
Therefore, even if autopsied tissues could be obtained, they
might manifest no convincing histological changes of base-
line uL-FABP elevation [32]. Second, because of the small
sample size in a single center, the statistical power for
detecting the impact of uL-FABP on the incidence of AKI
might be inadequate. Our results would be generalized if
data based on more samples from multiple international
centers are collected.
In conclusion, uL-FABP is a useful biomarker for
predicting the incidence of AKI in SCT recipients. We believe
that the current results support the value of the early
detection of and screening for pre-existing subclinical
kidney disease at baseline, using uL-FABP, as it is a simple
and easy noninvasive measurement to target patients at
increased risk of AKI after SCT. Further and larger scale
research on the clinical importance of detecting trivial yet
active kidney injury by using urinary biomarkers in SCT
candidates is warranted globally.
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